Lixisenatide Resensitizes The Insulin-Secretory Response To Intravenous Glucose Challenge T2D

Lixisenatide thereby accelerates glucose disposal to nearly physiological intensity, and does not impair counter-regulation to low glucose levels by glucagon (Diabetes, Obesity and Metabolism)